DDAVP infusion in five patients with type Ia glycogen storage disease and associated correction of prolonged bleeding times
- PMID: 3087438
DDAVP infusion in five patients with type Ia glycogen storage disease and associated correction of prolonged bleeding times
Abstract
Five patients with glycogen storage disease type I (GSD-I) were evaluated for a bleeding diathesis and subsequently were given an infusion of 1-deamino-8-D-arginine vasopressin (DDAVP). Although platelet counts were normal or slightly elevated, the baseline template bleeding times were prolonged in four of the patients. Prothrombin times and activated partial thromboplastin times were normal, while ADP- and epinephrine-induced platelet aggregations were absent in the three patients tested. Ristocetin- and collagen-induced platelet aggregations were abnormal. Laurell and immunoradiometric determinations of the factor VIII-related antigen (vWf antigen) were decreased. Glyoxyl agarose gel electrophoresis of the patients' plasma revealed abnormal multimer patterns in four of the five patients. After the DDAVP infusion the platelet aggregation abnormalities persisted; however, the bleeding time and the von Willebrand antigen and activity corrected. We conclude that GSD-Ia patients may have a metabolically acquired form of von Willebrand's syndrome as well as an acquired intrinsic platelet defect, and that DDAVP may be useful in the management of bleeding in these patients.
Similar articles
-
A probable double heterozygous type II von Willebrand's disease with increased ristocetin induced platelet aggregation.Am J Hematol. 1992 Jul;40(3):192-8. doi: 10.1002/ajh.2830400307. Am J Hematol. 1992. PMID: 1609773
-
Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.Blood. 1982 Jun;59(6):1272-8. Blood. 1982. PMID: 6805532
-
Effect of 1-deamino-8-D-arginine vasopressin on the prolonged bleeding time in chronic renal failure.Nephron. 1982;32(1):49-52. doi: 10.1159/000182801. Nephron. 1982. PMID: 6817151
-
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. doi: 10.1177/1076029606296399. Clin Appl Thromb Hemost. 2007. PMID: 17164493 Review.
-
[Desmopressin in the treatment of hemorrhagic diathesis].Ugeskr Laeger. 1995 Nov 27;157(48):6713-5. Ugeskr Laeger. 1995. PMID: 8540136 Review. Danish.
Cited by
-
Desmopressin (DDAVP) and hemostasis.Ann Hematol. 1994 Oct;69(4):173-80. doi: 10.1007/BF02215950. Ann Hematol. 1994. PMID: 7948303 Review.
-
Platelet glycogenolysis is important for energy production and function.Platelets. 2023 Dec;34(1):2222184. doi: 10.1080/09537104.2023.2222184. Platelets. 2023. PMID: 37292023 Free PMC article.
-
Acquired von Willebrand's disease.Ir J Med Sci. 1998 Apr-Jun;167(2):81-5. doi: 10.1007/BF02937942. Ir J Med Sci. 1998. PMID: 9638020
-
Clinical and biochemical footprints of inherited metabolic disease. XVI. Hematological abnormalities.Mol Genet Metab. 2023 Dec;140(4):107735. doi: 10.1016/j.ymgme.2023.107735. Epub 2023 Nov 13. Mol Genet Metab. 2023. PMID: 37989003 Free PMC article. Review.
-
Perioperative management of hemostasis for surgery of benign hepatic adenomas in patients with glycogen storage disease type ia.JIMD Rep. 2011;1:97-106. doi: 10.1007/8904_2011_23. Epub 2011 Jun 22. JIMD Rep. 2011. PMID: 23430835 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous